JP2004248677A5 - - Google Patents

Download PDF

Info

Publication number
JP2004248677A5
JP2004248677A5 JP2004113481A JP2004113481A JP2004248677A5 JP 2004248677 A5 JP2004248677 A5 JP 2004248677A5 JP 2004113481 A JP2004113481 A JP 2004113481A JP 2004113481 A JP2004113481 A JP 2004113481A JP 2004248677 A5 JP2004248677 A5 JP 2004248677A5
Authority
JP
Japan
Prior art keywords
pro
ctla4
tyr
soluble ctla4
extracellular domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004113481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004248677A (ja
Filing date
Publication date
Priority claimed from US08/228,208 external-priority patent/US6090914A/en
Application filed filed Critical
Publication of JP2004248677A publication Critical patent/JP2004248677A/ja
Publication of JP2004248677A5 publication Critical patent/JP2004248677A5/ja
Pending legal-status Critical Current

Links

JP2004113481A 1994-04-15 2004-04-07 Ｃｔｌａ４分子及びｉｌ４結合分子並びにそれらの使用 Pending JP2004248677A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/228,208 US6090914A (en) 1991-06-27 1994-04-15 CTLA4/CD28Ig hybrid fusion proteins and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP7115095A Division JPH0847391A (ja) 1994-04-15 1995-04-17 Ｃｔｌａ４分子及びｉｌ４結合分子並びにそれらの使用

Publications (2)

Publication Number Publication Date
JP2004248677A JP2004248677A (ja) 2004-09-09
JP2004248677A5 true JP2004248677A5 (cg-RX-API-DMAC7.html) 2005-09-02

Family

ID=22856248

Family Applications (2)

Application Number Title Priority Date Filing Date
JP7115095A Withdrawn JPH0847391A (ja) 1994-04-15 1995-04-17 Ｃｔｌａ４分子及びｉｌ４結合分子並びにそれらの使用
JP2004113481A Pending JP2004248677A (ja) 1994-04-15 2004-04-07 Ｃｔｌａ４分子及びｉｌ４結合分子並びにそれらの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP7115095A Withdrawn JPH0847391A (ja) 1994-04-15 1995-04-17 Ｃｔｌａ４分子及びｉｌ４結合分子並びにそれらの使用

Country Status (8)

Country Link
US (1) US6090914A (cg-RX-API-DMAC7.html)
EP (2) EP1666498A3 (cg-RX-API-DMAC7.html)
JP (2) JPH0847391A (cg-RX-API-DMAC7.html)
AU (1) AU701310B2 (cg-RX-API-DMAC7.html)
CA (1) CA2146895C (cg-RX-API-DMAC7.html)
FI (2) FI951801L (cg-RX-API-DMAC7.html)
IL (1) IL113343A (cg-RX-API-DMAC7.html)
NO (1) NO322278B1 (cg-RX-API-DMAC7.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6824779B1 (en) * 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
DK0892643T4 (da) * 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US20060034844A1 (en) * 1996-12-04 2006-02-16 The Regents Of The University Of California Stimulation of T cells against self antigens using CTLA-4 blocking agents
KR19980066046A (ko) * 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
WO1999015552A1 (en) * 1997-09-19 1999-04-01 Yoshitomi Pharmaceutical Industries, Ltd. Oligopeptide compounds
EP0947582A1 (en) * 1998-03-31 1999-10-06 Innogenetics N.V. A polypeptide structure for use as a scaffold
AU6615500A (en) * 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001030966A2 (en) * 1999-10-22 2001-05-03 Alexion Pharmaceuticals, Inc. An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CA2411962A1 (en) 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CZ303959B6 (cs) 2000-07-03 2013-07-17 Bristol-Myers Squibb Company Solubilní CTLA4 fúzní molekula, farmaceutický prostredek s jejím obsahem a její pouzití
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
PT1397153E (pt) 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2003048194A2 (de) * 2001-12-04 2003-06-12 Tegenero Ag Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
WO2003086459A1 (en) 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
RU2375077C2 (ru) * 2002-05-02 2009-12-10 Юниверсити Оф Коннектикут Хелт Сентер Использование белков теплового шока для повышения эффективности терапий антителами
JP2006500931A (ja) * 2002-09-30 2006-01-12 ファイザー・プロダクツ・インク 高レベルのヒト配列抗体を産生するハイブリドーマ
PL377731A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
PL377603A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Poprawa jakości produktu w hodowlach komórek ssaczych do wytwarzania białka
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP1670499A4 (en) * 2003-08-04 2009-07-22 Bristol Myers Squibb Co METHODS OF TREATING A CARDIOVASCULAR DISEASE USING A SOLUBLE CTLA4 MOLECULE
KR100545720B1 (ko) * 2004-05-31 2006-01-24 메덱스젠 주식회사 당화된 면역글로불린 및 이를 포함하는 면역접합체
US7453291B2 (en) * 2004-09-09 2008-11-18 The Regents Of The University Of California Switch linearized track and hold circuit for switch linearization
PL1868635T3 (pl) * 2005-04-06 2017-10-31 Bristol Myers Squibb Co Metody leczenia zaburzeń immunologicznych związanych z transplantacją narządów rozpuszczalnymi zmutowanymi cząsteczkami CTLA4
DK2298815T3 (en) 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
EP1954311A4 (en) 2005-12-07 2009-12-23 Medarex Inc CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
TWI423986B (zh) 2005-12-20 2014-01-21 必治妥美雅史谷比公司 組合物及製造組合物之方法
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
EP2222697B1 (en) * 2007-11-01 2012-12-05 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
RS51975B (sr) * 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
KR20180105731A (ko) 2008-10-02 2018-09-28 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
KR20130049775A (ko) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
EP2621514B1 (en) 2010-09-28 2016-09-21 KAHR Medical (2005) Ltd Compositions and methods for treatment of hematological malignancies
US9688740B2 (en) 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
WO2013062365A2 (ko) * 2011-10-26 2013-05-02 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3-BINDING POLYPEPTIDES
AU2018256436B2 (en) 2017-04-19 2024-12-05 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
EP4620972A4 (en) * 2022-11-18 2025-10-22 Seoul Nat Univ R&Db Foundation DUAL GENE TRANSDUCTION IMMUNE CELL USING CTLA-4 VARIANT AND CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
AU661854B2 (en) * 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
WO1994028912A1 (en) * 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression

Similar Documents

Publication Publication Date Title
JP2004248677A5 (cg-RX-API-DMAC7.html)
US12152060B2 (en) Interleukin-2 variants and methods of uses thereof
JP2023166395A5 (cg-RX-API-DMAC7.html)
JP2020521452A5 (cg-RX-API-DMAC7.html)
US8916155B2 (en) Method for the treatment of T cell mediated conditions by depletion of ICOS-positive cells in vivo
JP2020511949A5 (cg-RX-API-DMAC7.html)
JP2017527272A5 (cg-RX-API-DMAC7.html)
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
JP2010533498A5 (cg-RX-API-DMAC7.html)
JP2006526414A5 (cg-RX-API-DMAC7.html)
CN114728040A (zh) 新型白介素-2变体及其双功能融合分子
JP2019507589A5 (cg-RX-API-DMAC7.html)
JP2010511388A5 (cg-RX-API-DMAC7.html)
JP2006340714A5 (cg-RX-API-DMAC7.html)
WO2011113019A2 (en) Ctla4 proteins and their uses
JP2023081303A5 (cg-RX-API-DMAC7.html)
JP2012500006A5 (cg-RX-API-DMAC7.html)
JP2006523711A5 (cg-RX-API-DMAC7.html)
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2009517006A5 (cg-RX-API-DMAC7.html)
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2012500020A5 (cg-RX-API-DMAC7.html)
RU2011101969A (ru) Антитела к человеческому интерлейкину-20
RU2010136940A (ru) Антитела против альфа5-бета1 и их применение
JP2021505156A5 (cg-RX-API-DMAC7.html)